For instance, B3GNT7 and CTSV predicted detrimental prognosis in BRCA2-mut breast cancers, and CD6, CXCL9, and CXCL13 predicted favorable outcomes in BRCA1-mut ovarian cancers. This evidence concerns the gene CXCL9 and ovarian cancer.